

Antitumor activity of G-quadruplex-interactive agent TMPyP₄ with photodynamic therapy in ovarian carcinoma cells

HONGLI LIU, CHANGSHUAI LV, BAIJUAN DING, JIE WANG, SHAN LI and YOUZHONG ZHANG

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China

Received November 13, 2013; Accepted March 20, 2014

DOI: 10.3892/ol.2014.2125

Abstract. The aim of the present study was to investigate the potential effects of photodynamic therapy (PDT) mediated by the cationic porphyrin, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine (TMPyP₄), on an ovarian carcinoma cell line and the underlying mechanisms by which TMPyP₄-PDT exerts its actions. The analysis of cell viability, hematoxylin and eosin staining and flow cytometric apoptosis assays revealed that TMPyP₄-PDT potently suppressed the growth of the A2780 cells in a laser energy- and dose-dependent manner. Mechanically, it was observed that TMPyP₄-PDT suppressed the proliferation and motility of the A2780 cells. In addition, the expression levels of minichromosome maintenance protein-2 (MCM2) and carbonic anhydrase IX (CA-IX) were detected by western blot analysis. The results indicated that the TMPyP₄-PDT-induced apoptosis and antimetastatic activity in the A2780 cells was accompanied by the inhibition of the expression of MCM2 and CA-IX. Therefore, TMPyP₄-PDT may represent a potential therapeutic method for the treatment of ovarian carcinoma.

Introduction

As ovarian cancer cells are only superficially invasive and primarily disseminate within the peritoneal cavity, ovarian carcinoma biology differs from that of hematogenously metastasizing tumors. However, as ovarian carcinoma is only temporarily chemosensitive, presents with rapidly proliferating tumors that compress the visceral organs and has a cure rate of only 30%, the disease is lethal (1). Conventional treatments, including surgery, chemotherapy and radiation, are basically ineffective, as surgical procedures are limited by disease staging, chemotherapy may increase the risk of side-effects

and radiotherapy may cause serious local tissue injury(2-6). Therefore, the identification of a safe and effective therapy for the treatment of ovarian carcinoma is required.

Photodynamic therapy (PDT) is a novel technology for the treatment of tumors; it is a minimally invasive therapeutic modality that has been demonstrated to be effective in several types of cancer and non-oncological conditions (7). The cationic porphyrin, 5,10,15,20-tetra-(N-methyl-4-pyridyl) porphine (TMPyP₄), is a novel type of synthetic water-soluble photosensitizer. TMPyP₄ binds to and stabilizes G-quadruplexes and has been revealed to form G-quadruplexes in the promoter or regulatory regions of important oncogenes, including c-myc, c-myb, c-fos and c-Abl (8), as well as in the single-stranded G-rich overhangs of telomeres *in vitro* (9). Additionally, it has been reported that the nuclear-mitochondrial shuttling of telomerase reverse transcriptase and mitochondrial dysfunction are involved in the arrest of cell proliferation that is induced by the G-quadruplex ligand, TMPyP₄ (10). These observations indicate that the G-quadruplex structure presents a potential therapeutic target in tumor cells. However, the precise effect of TMPyP₄-PDT against ovarian carcinoma cells and the underlying molecular mechanisms have not yet been established.

In the current study, the apoptotic effect of TMPyP₄-PDT on tumor cells and the expression levels of minichromosome maintenance protein-2 (MCM2) and carbonic anhydrase (CA)-IX were investigated by analyzing the apoptotic rate of the human ovarian carcinoma A2780 cell line *in vitro* in order to highlight the clinical significance of TMPyP₄-PDT in the treatment of ovarian carcinoma patients.

Materials and methods

Cell lines and reagents. The human ovarian carcinoma A2780 cell line was obtained from the Cancer Center Laboratory of Shandong University (Jinan, Shandong, China) and cultured in RPMI-1640 (HyClone, Logan, UT, USA) and cultured in RPMI-1640 (HyClone, Logan, UT, USA) with 10% fetal bovine serum (FBS; HyClone), containing 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Shanghai Solarbio Bioscience and Technology Co., Ltd., Shanghai, China) in an atmosphere of 5% CO₂ and 100% humidity at 37°C.

TMPyP₄ was purchased from Calbiochem (San Diego, CA, USA) and was stored with minimal exposure to light. In addition, suspension cultures were exposed to a single laser at the

Correspondence to: Dr Youzhong Zhang, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, Shandong 250012, P.R. China
E-mail: zhangyouzhong@vip.sina.com

Key words: human ovarian carcinoma, photodynamic therapy, minichromosome maintenance protein-2, carbonic anhydrase IX, 5,10,15,20-tetra-(N-methyl-4-pyridyl) porphine

energy densities of 0, 3, 6 and 12 J/cm² by a 800-mW power and 630-nm wavelength semiconductor laser (B100, Zhengzhou Zhongxing Medical Equipment Co., Ltd., Henan, China).

The primary antibodies against anti-human MCM2 (rabbit polyclonal), anti-human CA-IX (rabbit monoclonal) and anti-human GAPDH (rabbit monoclonal), and horseradish peroxidase (HRP)-conjugated goat anti-rabbit and anti-mouse IgG were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).

Cell viability. The cell viability was assessed using the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, monosodium salt cell counting kit-8 (CCK-8) assay (Bestbio Biotechnology, Shanghai, China). Fresh cells were seeded in 96-well flat-bottomed tissue culture plates (Corning Inc., Corning, NY, USA) at a concentration of 4×10^3 cells/well with complete culture medium and incubated for 24 h. Following two washes with phosphate-buffered saline (PBS), the cells were incubated in 100 μ l culture medium containing 3, 6, 15, 30 or 60 μ M TMPyP₄ for 4 h. Next, cells at each concentration were exposed to the single laser at an energy density of 0, 3, 6 and 12 J/cm², respectively. Following irradiation, the cells were incubated in fresh medium for an additional 24 h at 37°C prior to the CCK-8 assay. A total of 10 μ l CCK-8 and 100 μ l RPMI-1640 culture medium was then added to each well, and following incubation for 1 h at 37°C, the optical densities of the samples were measured directly using a spectrophotometric microplate reader (Beyotime Institute of Biotechnology, Haimen, China) at a wavelength of 450 nm. Each experiment was performed in triplicate and repeated five times.

Morphological observations. Following treatment with TMPyP₄ for 4 h, the cells were incubated for an additional 24 h prior to morphological analysis of the cells observed under an inverted microscope (Olympus, Tokyo, Japan). The laser energy density was set at 6 J/cm² and the cells were stained using a hematoxylin and eosin staining kit (Beyotime Institute of Biotechnology).

Analysis of apoptotic cells. The apoptotic cells were identified using the Annexin V-fluorescein isothiocyanate apoptosis detection kit (Bestbio Biotechnology). The cells were then incubated for 24 h following irradiation and three washes with PBS. The cell concentration was then adjusted to 5×10^5 cells/ml. Next, the apoptotic cells were analyzed using FACSCalibur (BD Biosciences, San Jose, CA, USA), and the data was analyzed using FlowJo 7.6.1 software (TreeStar, Inc., Ashland, OR, USA).

Western blot analysis. Following treatment with 3, 6 or 15 μ M TMPyP₄ for 4 h and laser treatment, the cells were incubated for an additional 48 h prior to the collection cells for protein extraction. The examination of the expression levels of MCM2 and CA-IX was then performed separately. The laser energy density was set at 6 J/cm² and total protein was extracted with the radioimmunoprecipitation assay reagent in the presence of phosphatase protease inhibitors (Beyotime Institute of Biotechnology) and the bicinchoninic acid assay kit (Beyotime Institute of Biotechnology) was used to measure the protein




Figure 1. Effects of TMPyP₄-PDT on the cell growth of A2780 cells. In the TMPyP₄-PDT group, the cells were incubated with 3, 6, 15, 30 or 60 μ M TMPyP₄ and then exposed to single laser energy at densities of 0, 3, 6 and 12 J/cm² with a semiconductor laser. TMPyP₄, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine; PDT, photodynamic therapy.

concentration. The protein (50 μ g) was separated by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane using wet transfer apparatus (Bio-Rad, Hercules, CA, USA). The membranes were then blocked with 5% skimmed milk and incubated overnight at 4°C with the primary antibodies, followed by incubation with the secondary antibodies labeled with HRP. Next, the protein bands were visualized using an enhanced chemiluminescence kit (Millipore, Billerica, MA, USA) and the protein levels were detected using the chemiluminescence reader, ImageQuant™ LAS4000 (GE Healthcare, Pittsburgh, PA, USA), and analyzed by ImageJ software (US National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. Data are presented as the mean \pm standard deviation. Student's two-tailed t-test was used to determine the statistical differences between the treatment and control groups. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Effects of TMPyP₄-PDT on cell growth. The results showed that treatment with PDT alone at various laser energy densities did not significantly inhibit the growth of the A2780 cells ($P > 0.05$). However, treatment with TMPyP₄ alone at doses of 3, 6, 15, 30 or 60 μ M significantly inhibited the growth of the cells ($P < 0.05$) in a dose-dependent manner. Furthermore, treatment with TMPyP₄-PDT at doses of 3, 6, 15, 30 or 60 μ M also significantly inhibited the growth of the cells, and these inhibitory effects were observed to be in a laser energy- and dose-dependent manner ($P < 0.01$ and $P < 0.01$, respectively) (Fig. 1).

Effects of TMPyP₄-PDT on cell morphology. The cells in the blank control were observed to be polygonal or spindle-shaped. The cells treated with 3 μ M TMPyP₄ were partially round in shape, whereas cells treated with 6 μ M TMPyP₄ were in a poor state and adherent cells were sparse. Furthermore, with increasing TMPyP₄ concentration, the cells became increasingly round in shape and the number of adherent cells was significantly reduced. In addition, apoptotic bodies were clearly visible following treatment with 6 μ M TMPyP₄ (Fig. 2).

Under the conditions of the laser energy density set at 6 J/cm², the blank control group morphology was more consistent with




Figure 2. TMPyP₄-PDT induces various morphological changes in A2780 cells. Representative images of A2780 cells treated with TMPyP₄-PDT captured by inverted microscopy are shown (magnification, x200). (A) Blank control group and groups treated with TMPyP₄-PDT concentrations of (B) 3, (C) 6, (D) 15, (E) 30 and (F) 60 μ M were exposed to a single laser energy density of 6 J/cm². TMPyP₄, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine; PDT, photodynamic therapy.




Figure 3. TMPyP₄-PDT induces various morphological changes in A2780 cells. Representative hematoxylin and eosin staining images of A2780 cells captured by inverted microscopy are shown (magnification, x200). (A) Blank control group and groups treated with TMPyP₄-PDT concentrations of (B) 3, (C) 6, (D) 15, (E) 30 and (F) 60 μ M were exposed to a single laser energy density of 6 J/cm². TMPyP₄, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine; PDT, photodynamic therapy.

a high nuclear cytoplasm ratio. Furthermore, with increasing TMPyP₄-PDT concentration, the cell morphology of the TMPyP₄-PDT group became increasingly irregular and nuclear pyknosis or fragments were observed (Fig. 3).

Effects of TMPyP₄-PDT on cell apoptosis. Propidium iodide and Annexin V double-staining were used to detect the changes in apoptotic cells treated with TMPyP₄-PDT, and the apoptosis-inducing effects of TMPyP₄-PDT were assessed using FlowJo software. Under the conditions of the laser energy density set at 6 J/cm², the effects of TMPyP₄-PDT on the apoptosis of the A2780 cells was examined following treatment at doses

of 3, 6, 15, 30, or 60 μ M. The cells that were treated with the various doses of TMPyP₄ for 24 h showed a significant increase in the number of apoptotic bodies compared with the negative control group, and the apoptotic cell percentage increased in a dose-dependent manner. The cell apoptosis rates were 1.0 ± 0.10 , 14.7 ± 2.22 , 32.3 ± 1.69 , 52.2 ± 1.47 , 56.3 ± 1.23 and $80.3 \pm 3.14\%$ for doses of 3, 6, 15, 30, or 60 μ M TMPyP₄, respectively (Fig. 4).

Effects of TMPyP₄-PDT on the expression levels of MCM2 and CA-IX proteins. Following irradiation with a laser energy density of 6 J/cm² and treatment with TMPyP₄-PDT at doses of 3, 6 or 15 μ M, the MCM2 and CA-IX expression levels were analyzed.




Figure 4. TMPyP₄-PDT induces cell apoptosis in A2780 cells. The cells were cultured with 3, 6, 15, 30 or 60 μ M TMPyP₄ for 4 h prior to exposure to radiation and incubation at 37°C for 24 h. The apoptotic cells were identified using the fluorescent marker, Annexin V-fluorescein isothiocyanate (magnification, x200). (A) Blank control group and groups treated with TMPyP₄-PDT concentrations of (B) 3, (C) 6, (D) 15, (E) 30 and (F) 60 μ M were exposed to a single laser energy density of 6 J/cm². TMPyP₄, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine; PDT, photodynamic therapy.




Figure 5. TMPyP₄-PDT reduces the levels of MCM2 and CA-IX expression in A2780 cells. (A) Western blot analysis detected the levels of MCM2 and CA-IX expression in the A2780 cells, and GAPDH was used as a control. (B) Statistical graph of MCM2 and CA-IX expression. Significant differences in expression were identified between the groups for the two genes ($P < 0.05$). Data are presented as the mean \pm standard deviation of three independent experiments. * $P < 0.05$ and ** $P < 0.01$ vs. control group. TMPyP₄, 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine; PDT, photodynamic therapy; MCM2, minichromosome maintenance protein-2; CA-IX, carbonic anhydrase-IX.

In contrast to the increased apoptosis observed in A2780 cells, the expression levels of MCM2 and CA-IX were significantly downregulated in a dose-dependent manner (Fig. 5).

Discussion

PDT is minimally invasive, with good tolerance, improved aesthetic outcomes, minimal functional disturbance, low morbidity and the ability to be used more than once at the same site in comparison to surgery, radiation and chemotherapy. The main mechanism of PDT used for the diagnosis and treatment of cancer involves the use of sensitized molecular components, which transfer heat to generate singlet oxygen through a series of photochemical and photobiological reactions. Furthermore,

the generated singlet oxygen and the release of prostaglandins, lymphokines, thromboxane or other cytokines destroys the tumor microvessel and biofilm, thereby killing the tumor cells (11-14). TMPyP₄ is a tetravalent cationic water-soluble porphyrin that accumulates in tumors, with a good degree of selectivity (15,16). TMPyP₄ connects with telomeres and promotes telomerase ends to form a stable G-quadruplex structure, which reduces the telomerase activity and its role in tumor cells, and leads to the arrest of tumor cell growth, thus inducing the apoptosis of tumor cells (17,18). In the current study, the growth inhibition of the human ovarian carcinoma A2780 cells was not evident in the PDT group ($P > 0.05$). However, in the TMPyP₄ and TMPyP₄ PDT groups, the growth inhibition of the human ovarian carcinoma A2780 cells gradually increased

with increasing drug concentration and laser energy density, although, when the treatment reached a certain level, the inhibition of the cell increase slowed down ($P < 0.05$). Therefore, in clinical PDT, an appropriate dose of the photosensitizer and laser energy density must be selected, as blindly increasing the dose of the photosensitizer and laser energy density is not conducive to improving the efficacy and may lead to toxicity and side-effects as a result of the high dose. The effect of 5-aminolevulinic acid-mediated PDT on the induction of apoptosis has also been extensively described (19,20). Consistent with previous studies, a similar phenomenon was observed in the current study, whereby the TMPyP₄-PDT-induced cell apoptosis and the effect on the induction of apoptosis were in a laser energy- and dose-dependent manner (21).

MCM2 is one of the conserved set of six related proteins of the MCM complex (MCM2-7), which is essential in the regulation of DNA replication (22). MCM2 has been studied in a wide range of human organs, and its overexpression has been identified in various types of tumors and tumor-like lesions of the oral mucosa, larynx, stomach, colon, esophagus, breasts, lungs, ovaries, kidneys, prostate, bladder, brain and soft tissues (23,24). CA-IX is a member of the CA family, which are a group of zinc-containing metalloenzymes that catalyze the reversible hydration of carbon dioxide to carbonic acid and are involved in respiration and the acid-base balance (25). CA-IX is important in the regulation of cell proliferation and transformation, and is conducive to tumor growth and metastasis (26). The present study demonstrated that the antitumor effects of TMPyP₄-PDT are accompanied by the downregulation of MCM2 and CA-IX. According to this result, we hypothesized that TMPyP₄-PDT may inhibit the DNA replication of tumor cells and change pH homeostasis, thereby inhibiting tumor cell proliferation and metastasis. However, the specific mechanism of TMPyP₄-PDT requires further study.

In conclusion, the present study demonstrated that TMPyP₄-PDT potently suppressed the cell growth of the A2780 cells in a laser energy- and dose-dependent manner. In addition, the study indicated that TMPyP₄-PDT may exhibit its antitumor activity by downregulating the expression of MCM2 and CA-IX in human ovarian carcinoma cells. Furthermore, TMPyP₄ enhances laser sensitivity. These results indicated that TMPyP₄-PDT may be supplementary to conventional therapy in the treatment of ovarian carcinoma. Further study to clarify the molecular mechanism of the TMPyP₄-PDT-induced antitumor activity may provide a rationale for the development of anti-tumor drug targeted therapies for ovarian carcinoma.

Acknowledgements

The authors would like to thank the professors of the Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital of Shandong University (Jinan, Shandong, China). This study was supported by the National Natural Science Foundation (grant no. 81072122).

References

- Lengyel E: Ovarian cancer development and metastasis. *Am J Pathol* 177: 1053-1064, 2010.
- Jackson KS and Naik R: Pelvic floor dysfunction and radical hysterectomy. *Int J Gynecol Cancer* 16: 354-363, 2006.
- Bosgraaf RP, Mast PP, Struik-van der Zanden PH, *et al*: Overtreatment in a see-and-treat approach to cervical intraepithelial lesions. *Obstet Gynecol* 121: 1209-1216, 2013.
- Chen FP and Li XJ: A profile of radiotherapy side effects and complications in gynecological malignant tumors. *Int Med Health Guidance N* 15: 117-118, 2009.
- Hashimoto K: Radical operation of cervical cancer of the uterus (Okabayashi's method). *Sanfujinka No Jissai* 19: 348-351, 1970 (In Japanese).
- Koning CC, Wouterse SJ, Daams JG, *et al*: Toxicity of concurrent radiochemotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. *Clin Lung Cancer* 14: 481-487, 2013.
- Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. *Biochim Biophys Acta* 1776: 86-107, 2007.
- Lemarteleur T, Gomez D, Paterski R, *et al*: Stabilization of the c-myc gene promoter quadruplex by specific ligands' inhibitors of telomerase. *Biochem Biophys Res Commun* 323: 802-808, 2004.
- Gomez D, Paterski R, Lemarteleur T, *et al*: Interaction of telomestatin with the telomeric single-strand overhang. *J Biol Chem* 279: 41487-41494, 2004.
- Zhuang XY and Yao YG: Mitochondrial dysfunction and nuclear-mitochondrial shuttling of TERT are involved in cell proliferation arrest induced by G-quadruplex ligands. *FEBS Lett* 587: 1656-1662, 2013.
- Sang Hong: The present situation in the study on application of photodynamic therapy. *Clin Dermatol* 31: 332, 2002.
- Juarranz A, Jaén P, Sanz-Rodríguez F, *et al*: Photodynamic therapy of cancer. Basic principles and applications. *Clin Transl Oncol* 10: 148-154, 2008.
- Meng B, Wen BG, Li GY and Shen ZY: Research progress in the study of mechanism of apoptosis induced by photodynamic therapy. *Sheng Li Ke Xue Jin Zhan* 33: 269-272, 2002 (In Chinese).
- Saczko J, Chwilkowska A, Kulbacka J, *et al*: Photooxidative action in cancer and normal cells induced by the use of photofrin in photodynamic therapy. *Folia Biol (Praha)* 54: 24-29, 2008.
- Villanueva A, Caggiari L, Jori G and Milanese C: Morphological aspects of an experimental tumour photosensitized with a meso-substituted cationic porphyrin. *J Photochem Photobiol B* 23: 49-56, 1994.
- Yamakawa N, Ishikawa Y and Uno T: Solution properties and photocatalytic activity of cationic bis-porphyrins linked with a series of aliphatic diamines. *Chem Pharm Bull (Tokyo)* 49: 1531-1540, 2001.
- Liu W, Sun D and Hurley LH: Binding of G-quadruplex-interactive agents to distinct G-quadruplexes induces different biological effects in MiaPaCa cells. *Nucleosides Nucleotides Nucleic Acids* 24: 1801-1815, 2005.
- Guo K, Pourpak A, Beetz-Rogers K, *et al*: Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. *J Am Chem Soc* 129: 10220-10228, 2007.
- Chen X, Zhao P, Chen F, *et al*: Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. *Lasers Med Sci* 26: 69-78, 2011.
- He GF, Bian ML, Zhao YW, *et al*: A study on the mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in vitro and in vivo in cervical cancer. *Oncol Rep* 21: 861-868, 2009.
- Zhao YL, Cao Z and Xu CS: Effects of TMPyP₄-PDT on human tongue carcinoma Tca8113 cells in vitro. *Laser Journal* 4: 78-79, 2008.
- Bell SP and Dutta A: DNA replication in eukaryotic cells. *Annu Rev Biochem* 71: 333-374, 2002.
- Giaginis C, Vgenopoulou S, Vielh P and Theocharis S: MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. *Histol Histopathol* 25: 351-370, 2010.
- Torres-Rendon A, Roy S, Craig GT and Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. *Br J Cancer* 100: 1128-1134, 2009.
- Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med* 9: 677-684, 2003.
- Airley R, Lancaster J, Davidson S, *et al*: Glucose transporter GLUT-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. *Clin Cancer Res* 7: 928-934, 2001.